Molnupiravir, is an antiviral drug that prevents the reproduction of some RNA viruses. It is used to treat COVID-19 in people who have been infected with SARS-CoV-2.
Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine that works against viruses by causing copying errors during viral RNA replication.
Molnupiravir was first created to treat influenza at Emory University by Drug Innovation Ventures at Emory, the university's drug development firm (DRIVE). Ridgeback Biotherapeutics, a Miami-based company, then bought it and partnered with Merck & Co. to further develop the drug.
The drug's international nonproprietary name, Mjölnir, was inspired by Thor's hammer. The medicine, like a powerful blow from the god of thunder, is supposed to knock out the infection.
In October 2021, preliminary findings from a clinical trial (MOVe-OUT) suggest that molnupiravir medication may minimise the incidence of COVID-19-related hospitalisation and mortality.
The Philippine Food and Drug Administration (FDA) granted four hospitals in the Philippines a compassionate special permit (CSP) to get molnupiravir in October 2021.
Centurion Healthcare is an excellent manufacturer and supplier of Molnupiravir - an antiviral drug that prevents the reproduction of some RNA viruses. Our state-of-the-art manufacturing facility is capable of producing and exporting in bulk quantities. We are a recognised and distinguished supplier of Molnupiravir capsules in various regions of Latin America such as Panama, Guatemala, Dominican Republic, Venezuela, Ecuador, Guyana, Nicaragua and many more.
Our firms’ vision is of becoming the industry leader and achieves the position by the making of extensively well researched products. Owing to make our medicines more effective, we conduct a research and then prepare a safe composition. The components used by us are quality che...
Learn MoreCopyright © 2019 WebsiteExample. All Rights Reserved
